Ivonescimab, a Dual-Targeting Bispecific Antibody, Improves Progression-Free Survival in Squamous NSCLC
ascopost.com/issues/november-25-2025/ivonesci...Posted Dec 1, 2025, 4:09 AM UTC
20
ascopost.com
Loading comments…
Posted Dec 1, 2025, 4:09 AM UTC